These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31673353)

  • 1. Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines.
    He G; Yang P; Yan Q; Xiong C
    Antimicrob Resist Infect Control; 2019; 8():164. PubMed ID: 31673353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
    Grohskopf LA; Blanton LH; Ferdinands JM; Chung JR; Broder KR; Talbot HK; Morgan RL; Fry AM
    MMWR Recomm Rep; 2022 Aug; 71(1):1-28. PubMed ID: 36006864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-mismatched influenza B/Yamagata lineage viruses in Cuba, 2012-2013 season.
    Arencibia A; Piñón A; Acosta B; Fernandez L; Muné M; Valdés O; Savón C; Oropesa S; Gonzalez G; Roque R; Gonzalez G; Hernández B; Alfonso JM
    Infect Genet Evol; 2018 Mar; 58():110-114. PubMed ID: 29229320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
    BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017.
    Puzelli S; Di Martino A; Facchini M; Fabiani C; Calzoletti L; Di Mario G; Palmieri A; Affanni P; Camilloni B; Chironna M; D'Agaro P; Giannecchini S; Pariani E; Serra C; Rizzo C; Bella A; Donatelli I; Castrucci MR;
    BMC Infect Dis; 2019 Nov; 19(1):990. PubMed ID: 31752738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
    Reed C; Meltzer MI; Finelli L; Fiore A
    Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the case for trivalent or quadrivalent influenza vaccines.
    Baxter D
    Hum Vaccin Immunother; 2016 Oct; 12(10):2712-2717. PubMed ID: 27435025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant circulation of influenza B viruses mismatching the recommended vaccine-lineage in South Korea, 2007-2014.
    Noh JY; Choi WS; Song JY; Lee HS; Lim S; Lee J; Seo YB; Lee JS; Wie SH; Jeong HW; Heo JY; Kim YK; Park KH; Kim SW; Lee SH; Lee JH; Kim DH; Woo SI; Lim CS; Cho KS; Cheong HJ; Kim WJ
    Vaccine; 2018 Aug; 36(35):5304-5308. PubMed ID: 30057284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale for quadrivalent influenza vaccines.
    Ambrose CS; Levin MJ
    Hum Vaccin Immunother; 2012 Jan; 8(1):81-8. PubMed ID: 22252006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season.
    Barr IG; McCauley J; Cox N; Daniels R; Engelhardt OG; Fukuda K; Grohmann G; Hay A; Kelso A; Klimov A; Odagiri T; Smith D; Russell C; Tashiro M; Webby R; Wood J; Ye Z; Zhang W;
    Vaccine; 2010 Feb; 28(5):1156-67. PubMed ID: 20004635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.
    Skowronski DM; Chambers C; De Serres G; Dickinson JA; Winter AL; Hickman R; Chan T; Jassem AN; Drews SJ; Charest H; Gubbay JB; Bastien N; Li Y; Krajden M
    Euro Surveill; 2018 Feb; 23(5):. PubMed ID: 29409570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.
    Ray R; Dos Santos G; Buck PO; Claeys C; Matias G; Innis BL; Bekkat-Berkani R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1640-1652. PubMed ID: 28532276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza surveillance in Western Turkey in the era of quadrivalent vaccines: A 2003-2016 retrospective analysis.
    Meşe S; Uyanik A; Özakay A; Öztürk S; Badur S
    Hum Vaccin Immunother; 2018; 14(8):1899-1908. PubMed ID: 29543569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for quadrivalent vaccine against seasonal influenza.
    Belshe RB
    Vaccine; 2010 Sep; 28 Suppl 4():D45-53. PubMed ID: 20713260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.